High transdominant RevM10 protein levels are required to inhibit HIV-1 replication in cell lines and primary T cells: Implication for gene therapy of AIDS

Gene Therapy

Volumn 4, Issue 2, 1997, Pages 128-139

  Plavec, I ^a   Agarwal, M ^a   Ho, K E ^b   Pineda, M ^a   Auten, J ^a   Baker, J ^a   Matsuzaki, H ^c   Escaich, S ^d   Bonyhadi, M ^a   Bohnlein E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b GENENTECH INC   (United States)

^c Affymetrix Corporation   (United States)

^d SANOFI   (France)

Author keywords

Gene therapy; HIV 1 retroviral vectors; T cells; Transgene expression

Indexed keywords

CD4 ANTIGEN; REV PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ARTICLE; CLONING VECTOR; CONTROLLED STUDY; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; SARCOMA VIRUS; T LYMPHOCYTE; VIRUS REPLICATION;

ANIMALIA; CUCUMBER MOSAIC VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; MYELOPROLIFERATIVE SARCOMA VIRUS; ONCOVIRINAE;

EID: 8044227784     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300369     Document Type: Article

References (60)

1. Cullen BR. Regulation of HIV-1 gene expression. FASEB J 1991; 5: 2361-2368.
2. Felber BK, Pavlakis GN. Molecular biology of HIV-1: positive and negative regulatory elements important for virus expression. AIDS 1993; 7: 51-62.
3. Rosen CA. Regulation of HIV gene expression by RNA-protein interactions. Trends Genet 1991; 7: 9-14.
4. Malim MH et al. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 1989; 338: 254-257.
5. Fischer U et al. The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 1995; 82: 475-483.
6. Bogerd HP et al. Identification of a novel cellular cofactor for the Rev/Rex class of retroviral regulatory proteins. Cell 1995; 82: 485-494.
7. Fritz CC, Zapp ML, Green MR. A human nucleoporin-like protein that specifically interacts with HIV Rev. Nature 1995; 376: 530-533.
8. Ruhl M et al. Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type 1 Rev activation domain mediating trans-activation. J Cell Biol 1993; 123: 1309-1320.
9. Malim MH et al. Functional dissection of the HIV-1 Rev trans-activator - derivation of a trans-dominant repressor of Rev function. Cell 1989; 58: 205-214.
10. + T lymphocytes by retroviral vectors expressing anti-HIV genes. J Virol 1995; 69: 4045-4052.
11. Woffendin C et al. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci USA 1994; 91: 11581-11585.
12. Malim MH et al. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J Exp Med 1992; 176: 1197-1201.
13. Escaich S et al. RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells. Hum Gene Ther 1995; 6: 625-634.
14. Bevec D et al. Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci USA 1992; 89: 9870-9874.
15. Bahner I et al. Comparison of trans-dominant inhibitory mutant human immunodeficiency virus genes expressed by retroviral vectors in human T lymphocytes. J Virol 1993; 67: 3199-3207.
16. Gilboa E, Smith C. Gene therapy for infectious diseases: the AIDS model. Trends Genet 1994; 10: 139-144.
17. Baltimore D. Intracellular immunization. Nature 1988; 335: 395-396.
18. Nabel GJ et al. A molecular genetic intervention for AIDS -effects of a transdominant negative form of Rev. Hum Gene Ther 1995; 5: 79-92.
19. Woffendin C et al. Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci USA 1996; 93: 2889-2894.
20. Miller AD Human gene therapy comes of age. Nature 1992; 357: 455-460.
21. Naviaux RK, Verma IM. Retroviral vectors for persistent expression in vivo. Curr Opin Biotech 1992; 3: 540-547.
22. Williams DA. Expression of introduced genetic sequences in hematopoietic cells following retroviral mediated gene transfer. Hum Gene Ther 1990; 1: 229-239.
23. Jolly D. Viral vector system for gene therapy. Cancer Gene Ther 1994, 1: 51-64.
24. Rivière I, Brose K, Mulligan RC. Effect of retroviral vector design on expression of human adenosine deammase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci USA 1995; 92: 6733-6737.
25. Lynch CM et al. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 1993; 4: 259-272.
26. Apperley JF, Luskey BD, Williams DA. Retroviral gene transfer of human adenosine deaminase in murine hematopoietic cells: effect of selectable marker sequences on long-term expression. Blood 1991; 78: 310-317.
27. Boshart M et al. A very strong enhancer is located upstream of an immediate-early gene of human cytomegalovirus. Cell 1985; 41: 521-530.
28. Adra CM, Boer PH, McBurney MW. Cloning and expression of the mouse pgk-1 gene and the nucleotide sequence of its promoter. Gene 1987; 60: 65-74.
29. Rigg RJ et al. Detection of intracellular HIV-1 Rev protein by flow cytometry. J Immunol Meth 1995; 188: 187-195.
30. Artelt P et al. The prokaryotic neomycin-resistance-encoding gene acts as a transcriptional silencer in eukaryotic cells. Gene 1991; 99: 249-254.
31. Challita PM et al. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 1995; 69: 748-755.
32. Flanagan JR et al. Negative control region at the 5′ end of murine leukemia virus long terminal repeats. Mol Cell Biol 1989; 9: 739-746.
33. Berwin B, Barklis E. Retrovirus-mediated insertion of expressed and non-expressed genes at identical chromosomal locations. Nucleic Acids Res 1993; 21: 2399-2407.
34. Beck-Engeser G et al. Retroviral vectors related to the myeloproliferative sarcoma virus allow efficient expression in hematopoietic stem and progenitor cell lines, but retroviral infection is reduced in more primitive cells. Hum Gene Ther 1991; 2: 61-70.
35. Colicelli J, Goff SP. Isolation of a recombinant murine leukemia virus utilizing a new primer tRNA. J Virol 1986; 57: 37-45.
36. Cepko CL, Roberts BE, Mulligan RC. Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell 1984; 37: 1053-1062.
37. Palmiter RD et al. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991; 88: 478-482.
38. Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Bio Techniques 1989; 7: 980-990.
39. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
40. Bender MA et al. Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J Virol 1987; 61: 1639-1646.
41. Tagawa M et al. Formal proof that different-size Lyt-2 polypeptides arise from differential splicing and post-transcriptional regulation. Proc Natl Acad Sci USA 1986; 83: 3422-3426.
42. Jang SK et al. Initiation of protein synthesis by internal entry of ribosomes into 5′ nontranslated region of encephalomyocarditis virus RNA in vivo. J Virol 1989; 63: 1651-1660.
43. Plavec I et al. Sustained retroviral gene marking and expression in lymphoid and myeloid cells derived from transduced hematopoietic progenitor cells. Gene Therapy 1996; 3: 717-724.
44. Kotani H et al. Improved method of retroviral vector transduction and production for gene therapy. Hum Gene Ther 1994; 5: 19-28.
45. - T cells in acute HIV infection in vitro. J Immunol 1993; 150: 5202-5208.
46. Zack JA et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990; 61: 213-222.
47. Salmon P et al. Characterization of the human CD4 gene promoter: transcription from the CD4 gene core promoter is tissue-specific and is activated by Ets proteins. Proc Natl Acad Sci USA 1993; 90: 7739-7743.
48. Mavilio F et al. Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. Blood 1994; 83: 1988-1997.
49. Hawley RG et al. Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus. J Exp Med 1992; 176: 1149-1164.
50. Baum C et al. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995; 69: 7541-7547.
51. Brenner MK. Human somatic gene therapy: progress and problems. J Int Med 1995; 237: 229-239.
52. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.
53. Ferry N et al. Retroviral mediated gene transfer into hepatocytes in vitro. Proc Natl Acad Sci USA 1991; 88: 8377-8381.
54. Pear WS et al. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 1993; 90: 8392-8396.
55. Miller AD, Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 1986; 6: 2895-2902.
56. Forestell SP, Bohnlein E, Rigg RJ. Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production. Gene Therapy 1995; 2: 723-730.
57. Haapala DK et al. Isolation from cats of an endogenous type C virus with a novel glycoprotein. J Virol 1985; 53: 827-833.
58. Valent P et al. Interleukin 4 promotes expression of mast cell ICAM-1 antigen. Proc Natl Acad Sci USA 1991; 88: 3339-3342.
59. Leland DS, French MLV. Virus isolation and identification. In: Lennette EH, Halonen P, Murphy FA (eds). Laboratory Diagnosis of Infectious Diseases: Principles and Practice. Springer-Verlag New York, 1988, pp 39-59.
60. Vandekerckhove BA et al. Human hematopoietic cells and thymic epithelial cells induce tolerance via different mechanisms in the SCID-hu mouse thymus. J Exp Med 1992; 175: 1033-1043.